Last updated: September 2, 2026
Glyburide/metformin hydrochloride is a mature, low-cost generic combination for type 2 diabetes. Its commercial trajectory is defined by declining branded revenue, fragmented generic supply, limited patent protection, and substitution toward newer therapies such as GLP-1 receptor agonists, dual GIP/GLP-1 agonists, and SGLT2 inhibitors. Glyburide and metformin remain clinically relevant in price-sensitive markets, but the fixed-dose combination has limited growth potential in the United States.
What is glyburide/metformin hydrochloride?
Glyburide/metformin hydrochloride combines two oral antihyperglycemic agents:
| Component |
Pharmacologic class |
Primary role |
| Glyburide, also called glibenclamide |
Sulfonylurea |
Stimulates pancreatic insulin secretion |
| Metformin hydrochloride |
Biguanide |
Reduces hepatic glucose production and improves insulin sensitivity |
The combination was marketed in the United States under the brand name Glucovance. The original product was approved by the FDA in 2000 for adults with type 2 diabetes inadequately controlled on glyburide or metformin alone, or for patients already receiving both agents separately [1].
Typical tablet strengths include:
- Glyburide/metformin 1.25 mg/250 mg
- Glyburide/metformin 2.5 mg/500 mg
- Glyburide/metformin 5 mg/500 mg
Higher metformin strengths and different dosing schedules are available in generic products depending on manufacturer and market.
What is the FDA regulatory status of glyburide/metformin?
Glyburide/metformin is an FDA-approved immediate-release oral prescription drug. Generic versions are approved through abbreviated new drug applications, or ANDAs, demonstrating pharmaceutical equivalence and bioequivalence to the reference product.
The product does not have biologic-drug status and has no biosimilar pathway. Its competitive pathway is generic substitution rather than biosimilar competition.
Metformin remains a foundational treatment for type 2 diabetes, although treatment guidelines increasingly position it alongside or after therapies selected for cardiovascular, kidney, obesity, or hypoglycemia considerations. Glyburide has a less favorable safety profile than several newer sulfonylureas because of prolonged hypoglycemia risk, particularly in older adults and patients with impaired renal function [2, 3].
The FDA labeling identifies important risks:
- Severe or prolonged hypoglycemia from glyburide
- Lactic acidosis risk associated with metformin
- Renal-function limitations for metformin
- Greater hypoglycemia risk in elderly patients, patients with renal impairment, and patients with inconsistent food intake
The FDA has also advised against using glyburide in certain older populations when safer alternatives are available. The American Geriatrics Society Beers Criteria identifies glyburide as a medication with a higher risk of prolonged hypoglycemia in older adults [4].
What patents protect glyburide/metformin hydrochloride?
The original combination product is effectively a post-patent pharmaceutical asset. Core composition and use protections associated with the branded product have expired or are no longer commercially meaningful in the United States.
| IP category |
Commercial position |
| Glyburide compound patents |
Expired |
| Metformin compound patents |
Expired |
| Original fixed-dose combination protection |
Expired or no longer blocking routine generic entry |
| Immediate-release tablet protection |
No meaningful current barrier |
| Method-of-use patents |
No material exclusivity supporting the U.S. product |
| Manufacturing know-how |
Limited practical barrier because multiple manufacturers produce equivalent tablets |
The Orange Book remains the principal FDA source for identifying listed patents and regulatory exclusivity for approved products [5]. For a mature generic combination such as glyburide/metformin, patent risk is generally less important than manufacturing economics, product availability, procurement contracts, and pharmacy substitution.
Any remaining patents would need to be assessed product by product and jurisdiction by jurisdiction. Secondary patents covering a particular formulation, manufacturing process, or delivery system would not necessarily block conventional immediate-release generic tablets.
When did glyburide/metformin lose exclusivity?
The fixed-dose combination lost meaningful commercial exclusivity after the branded product's generic competition became established. The key commercial transition occurred in the mid-2000s, when generic versions entered the U.S. market following expiry of relevant regulatory and patent barriers.
The product now has:
- No meaningful U.S. brand premium
- No market exclusivity supporting premium pricing
- No orphan-drug exclusivity
- No pediatric exclusivity of current commercial significance
- No biologic exclusivity
- No material protection from Paragraph IV litigation
Metformin itself has been generic for decades. Glyburide has also been generic for decades. The combination therefore competes in a fully mature market.
How many manufacturers sell glyburide/metformin?
The U.S. market has historically included several generic manufacturers and labelers, although the number of active suppliers changes with commercial demand and manufacturing decisions. Generic products have been marketed by companies including:
- Amneal Pharmaceuticals
- Ascend Laboratories
- AvKare
- Glenmark Pharmaceuticals
- Lupin Pharmaceuticals
- Mylan, now part of Viatris
- Sandoz
- Solco Healthcare
- Teva Pharmaceuticals
- Zydus Pharmaceuticals
Not every company is continuously active in every strength or package size. A manufacturer may maintain an approved ANDA while reducing or suspending commercial distribution.
Supply is influenced by:
- Low unit prices
- Limited reimbursement upside
- Active-ingredient and excipient costs
- Contracting with wholesalers and pharmacy chains
- Manufacturing-site compliance
- Product recalls or supply interruptions
- The number of competing suppliers
The combination has relatively low technical complexity. It is an immediate-release tablet rather than a sterile injectable, complex inhaled product, long-acting depot, or modified-release delivery system. Manufacturing barriers are therefore modest.
What is the market size for glyburide/metformin?
Reliable public revenue estimates for glyburide/metformin are limited because the product is generic, sold by multiple manufacturers, and often included in broader oral diabetes categories.
The principal commercial indicators are prescription volume, tablet volume, average selling price, and reimbursement. Reported manufacturer revenue is generally not disclosed separately because:
- Products are sold under multiple private-label and generic names
- Several companies distribute the same formulation
- Public companies aggregate the product within broader portfolios
- Net prices vary by wholesaler, payer, and contract
- Pharmacy benefit managers may reimburse based on generic reference pricing
The U.S. market is therefore a volume market rather than a branded-revenue market. Even a stable prescription base does not imply attractive manufacturer economics.
Revenue exposure by market segment
| Segment |
Revenue outlook |
| Original branded Glucovance |
Minimal or commercially inactive in the United States |
| U.S. generic tablets |
Low revenue per prescription; stable but mature demand |
| Retail pharmacy |
Price-sensitive and substitution-driven |
| Institutional and government procurement |
High volume, low margin |
| International markets |
Greater use in lower-income markets, but pricing remains constrained |
| Combination product development |
Low likelihood of premium pricing without differentiated delivery or adherence benefits |
How does glyburide/metformin compare with newer diabetes drugs?
Glyburide/metformin competes against a wide range of treatments, but its strongest economic competition comes from therapies that provide benefits beyond glucose reduction.
| Therapy |
Main commercial advantage over glyburide/metformin |
Market effect |
| Metformin alone |
Lower cost and simpler prescribing |
Reduces demand for the combination when separate titration is preferred |
| Glimepiride or glipizide |
Often viewed as more manageable sulfonylureas |
Can displace glyburide-containing regimens |
| DPP-4 inhibitors |
Lower hypoglycemia risk |
Higher price but weaker growth than GLP-1 and SGLT2 classes |
| SGLT2 inhibitors |
Cardiovascular and renal outcomes |
Strong substitution in patients with kidney or heart disease |
| GLP-1 receptor agonists |
Weight loss and glucose control |
Major competitive pressure in obesity-linked diabetes |
| Tirzepatide |
High efficacy for glucose and weight reduction |
Expands premium treatment segment |
| Insulin |
Greater glucose-lowering potency |
Used when oral therapy is inadequate |
The economic difference is substantial. Glyburide/metformin is generally purchased as a low-cost generic. GLP-1 receptor agonists, SGLT2 inhibitors, and tirzepatide are protected by active patents and brand-based pricing, although that pricing is offset by payer restrictions and access controls.
Clinical guidelines favor treatment selection based on comorbid cardiovascular disease, chronic kidney disease, heart failure, weight goals, hypoglycemia risk, and patient preference. These factors reduce the strategic value of glyburide/metformin even when its acquisition price is low [2, 3].
What generic entry risks exist for glyburide/metformin?
The original product has no meaningful future generic-entry event because generic entry has already occurred. The relevant risk is continued price erosion and product rationalization.
Generic manufacturers face four main risks:
Price compression
Multiple suppliers can drive average selling prices toward marginal manufacturing cost. Pharmacy benefit managers and wholesalers can shift volume rapidly between labelers.
Demand migration
Patients may move from glyburide-containing regimens to metformin alone, newer agents, insulin, or alternative sulfonylureas.
Safety-driven prescribing changes
Hypoglycemia concerns can discourage glyburide use in elderly and renally impaired patients. This is a demand risk rather than a patent risk.
Regulatory and supply risk
FDA manufacturing observations, recalls, import controls, or shortages of active pharmaceutical ingredients can affect supply. Because margins are thin, manufacturers may leave the market rather than invest in remediation or capacity expansion.
Are there Paragraph IV challenges involving glyburide/metformin?
Paragraph IV litigation is not a current commercial issue for the mature glyburide/metformin combination. Paragraph IV certifications are relevant when an ANDA applicant challenges an unexpired patent listed for a reference product. The core patents for this product class are expired, and routine generic supply is well established.
Any litigation involving a specific manufacturer would more likely concern:
- Manufacturing defects
- Product liability
- Labeling
- Contract disputes
- Anti-counterfeiting or distribution issues
- A formulation-specific patent unrelated to the standard immediate-release tablet
The absence of active Paragraph IV activity limits litigation-driven delay risk for new entrants.
What formulation patents protect glyburide/metformin?
Conventional immediate-release glyburide/metformin tablets have limited formulation differentiation. The commercially relevant product is a standard fixed-dose combination designed to reduce pill burden and simplify administration.
Potentially protectable features could include:
- Modified-release metformin
- Gastric-retentive delivery
- Bilayer tablet architecture
- Taste masking
- Stabilization of the active ingredients
- Alternative excipient systems
- Controlled dissolution profiles
These features would need a separate patent and regulatory strategy. They would not automatically protect standard immediate-release tablets.
The market has little evidence that a differentiated glyburide/metformin formulation could command a durable premium. Prescribers and payers have inexpensive alternatives, while the clinical value proposition is weaker than for newer therapies with outcome benefits.
What manufacturing and intellectual-property barriers exist?
Manufacturing barriers are low relative to complex pharmaceutical products.
| Barrier |
Assessment |
| Chemical synthesis |
Low to moderate |
| Tablet manufacturing |
Low |
| Sterility requirements |
Not applicable |
| Cold-chain requirements |
Not applicable |
| Device dependency |
None |
| Bioequivalence complexity |
Manageable for immediate-release tablets |
| API sourcing |
Multiple global sources, subject to quality and supply risks |
| Patent blocking risk |
Low |
| Regulatory filing cost |
Modest compared with new molecular entities |
| Commercial launch economics |
Challenging because of low prices |
The primary barrier is economic, not technological. A new entrant may obtain approval but still fail to achieve sufficient volume or margin.
What is the financial trajectory for glyburide/metformin?
The financial trajectory is mature to declining in developed markets.
Historical phase
The product initially benefited from:
- Fixed-dose convenience
- Use in patients requiring dual therapy
- Brand positioning before broad generic competition
- Metformin's role as a first-line treatment
Generic phase
After generic entry, pricing declined. Volume persisted because diabetes prevalence increased and the combination remained inexpensive, but the value shifted from branded sales to high-volume generic distribution.
Current phase
Current commercial performance is shaped by:
- Stable but limited residual demand
- Low generic prices
- Declining use of glyburide in older and high-risk patients
- Competition from therapies with weight, renal, and cardiovascular benefits
- Payer preference for low-cost generics in patients without comorbidity-driven indications
Forward outlook
The most likely trajectory is:
| Time horizon |
Expected market direction |
| Near term |
Stable low-value generic demand |
| Medium term |
Gradual volume erosion in the United States |
| Longer term |
Continued use in cost-sensitive and international markets |
| Premium revenue opportunity |
Very limited without a differentiated formulation |
| Litigation-driven value |
Low |
| Licensing value |
Low for the standard combination |
Revenue exposure for a generic manufacturer is likely to remain small unless the company controls a large institutional contract, has unusually efficient manufacturing, or sells the product in a market where fixed-dose combinations are widely used.
Which companies are challenging the incumbent market position?
The relevant challengers are not single patent litigants. They are manufacturers and therapeutic classes competing through price, formulary placement, and clinical positioning.
Generic manufacturers compete for supply contracts and pharmacy volume. Larger diabetes companies compete for treatment budgets through products such as:
- Novo Nordisk's semaglutide products
- Eli Lilly's tirzepatide and dulaglutide products
- AstraZeneca's dapagliflozin products
- Merck's sitagliptin products
- Sanofi and other insulin manufacturers
These companies do not compete directly on tablet price. They compete for patients whose treatment decisions are influenced by weight reduction, cardiovascular risk, kidney protection, convenience, and treatment durability.
What is the commercial investment case?
Glyburide/metformin has a defensive generic profile rather than a growth profile.
Potential advantages include:
- Established clinical familiarity
- Low manufacturing complexity
- Low development risk for approved generic products
- Continued demand in price-sensitive markets
- Use where newer therapies are inaccessible or unaffordable
Constraints include:
- No meaningful patent moat
- Limited pricing power
- High substitution risk
- Safety concerns associated with glyburide
- Strong competition from metformin monotherapy
- No meaningful brand premium
- Limited licensing value
- Weak prospects for significant U.S. revenue growth
The strongest commercial strategy is operational efficiency, reliable supply, and targeted international distribution. A strategy based on U.S. premium pricing, patent extension, or major branded growth has limited credibility.
Key Takeaways
- Glyburide/metformin hydrochloride is a mature fixed-dose generic combination for type 2 diabetes.
- The branded Glucovance opportunity has largely ended in the United States.
- Core compound and combination protections are expired or commercially non-blocking.
- There is no meaningful current biosimilar, Paragraph IV, or patent-litigation risk for standard immediate-release tablets.
- Generic revenue is low per prescription and depends on volume, supply reliability, and contracting.
- Glyburide faces clinical pressure because of prolonged hypoglycemia risk, especially in older adults and patients with renal impairment.
- GLP-1 receptor agonists, tirzepatide, SGLT2 inhibitors, and other outcome-oriented therapies are taking treatment share.
- The product's best remaining markets are cost-sensitive settings and international markets.
- Manufacturing barriers are modest; the principal obstacle is weak economics.
- The expected financial trajectory is stable to declining volume with continued price pressure.
FAQs
Is glyburide/metformin still available in the United States?
Generic glyburide/metformin products have been marketed in the United States, although availability varies by strength, manufacturer, wholesaler, and pharmacy inventory.
Is glyburide/metformin more effective than metformin alone?
The combination can reduce glucose levels more than metformin alone in patients who require dual therapy, but glyburide increases hypoglycemia risk. Treatment choice depends on renal function, age, glycemic targets, comorbidities, and access to newer medicines.
Does glyburide/metformin have an active patent?
The core product is a mature generic combination, and no broad patent barrier is generally expected to block standard immediate-release generic tablets in the United States.
Can a new company obtain FDA approval for glyburide/metformin?
A company can pursue an ANDA if it meets FDA requirements for pharmaceutical equivalence, bioequivalence, manufacturing quality, labeling, and active-ingredient sourcing. Approval does not guarantee commercially viable sales.
Is glyburide/metformin a potential licensing asset?
The standard generic combination has limited licensing value. A transaction would be more likely to involve manufacturing capacity, regional distribution rights, or a differentiated formulation than the underlying active ingredients.
References
-
U.S. Food and Drug Administration. (2000). FDA approves Glucovance for treatment of type 2 diabetes. FDA drug approval materials.
-
American Diabetes Association Professional Practice Committee. (2024). 9. Pharmacologic approaches to glycemic treatment: Standards of care in diabetes-2024. Diabetes Care, 47(Supplement 1), S158-S178.
-
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., & Buse, J. B. (2022). Management of hyperglycaemia in type 2 diabetes, 2022: A consensus report by the ADA and EASD. Diabetologia, 65, 1925-1966.
-
American Geriatrics Society Beers Criteria Update Expert Panel. (2023). American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society, 71(7), 2052-2081.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: The Orange Book. FDA.
